Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

NCT01765426 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL: TDV
DRUG: Placebo

Sponsor

Takeda

Collaborators

[object Object]